Skip to main content
. 2023 Aug 10;13(8):e1352. doi: 10.1002/ctm2.1352

FIGURE 6.

FIGURE 6

AF9 targets PCK2 and FBP1 through H3K9 acetylation (H3K9ac) but not H3K18ac. (A) Co‐immunoprecipitation (IP) was performed to test the association between AF9 and H3K9ac, H3K18ac in HT29 and HCT116 cells. (B) Chip assay was performed to test AF9 targeting the regions of PCK2 and FBP1 promoters. (C) Co‐IP was performed to test the association between AF9 and H3K9ac in HCT116 and RKO cells expressing wild type or mutant AF9. AF9 mutant: Y78A mutation. (D) In HCT116 and RKO cells, ChIP assay was performed to test wild type or mutant AF9 targeting the promoter of PCK2 and FBP1. (E) PCK2 and FBP1 expressed in HCT116 and RKO cells expressing wild type or mutant AF9. Vec was used as an empty control (**p < .01, ***p < .001).